Safety of plasmin in the setting of concomitant aspirin and heparin administration in an animal model of bleeding

Journal of Thrombosis and Haemostasis

Volumn 1, Issue 12, 2003, Pages 2621-2625

  Sadeghi, S ^a,b   Marder, V J ^a,b   Stewart, D ^a,b   Kong, M ^a   Humphries, J ^c   Baumbach, G A ^c   Jesmok, G ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BAYER CORPORATION   (United States)

Author keywords

Aspirin; Heparin; Plasmin; Safety

Indexed keywords

ACETYLSALICYLIC ACID; FIBRINOLYTIC AGENT; HEPARIN; PLASMIN;

ANIMAL; ANIMAL MODEL; ARTICLE; BLEEDING; BLEEDING TIME; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; DRUG INTERACTION; FIBRINOLYTIC THERAPY; RABBIT;

ANIMALS; ASPIRIN; BLEEDING TIME; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FIBRINOLYTIC AGENTS; HEMORRHAGE; HEPARIN; MODELS, ANIMAL; PLASMIN; RABBITS; THROMBOLYTIC THERAPY;

EID: 1542440237     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1046/j.1538-7836.2003.00441.x     Document Type: Article

References (27)

1. Comerota AJ, Aldridge SC, Cohen G, Ball DS, Pliskin M, White JV. A strategy of aggressive regional therapy for acute iliofemoral venous thrombosis with contemporary venous thrombectomy or catheter-di-rected thrombolysis. J Vasc Surg 1994; 20: 244-54.
2. Mewissen MW, Seabrook GR, Meissner MH, Cynamon J, Labropoulos N, Haughton SH. Catheter-directed thrombolysis for lower extremity deep venous thrombosis: report of a national multicenter registry. Radiology 1999; 211: 39-49.
3. Glynn MF, Langer B, Jeejeebhoy KN. Therapy for thrombotic occlusion of long-term intravenous alimentation catheters. J Parenter Enteral Nutr 1980; 4: 387-90.
4. Ouriel K, Shortell CK, De Weese JA, Green RM, Francis CW, Azodo MVU, Gutierrez OS, Manzione JV, Cox C, Marder VJ. A comparison of thrombolytic therapy with operative revascularization in the initial treatment of acute peripheral arterial ischmia. J Vasc Surg 1994; 19: 1021-30.
5. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, Pessin M, Ahuia A, Callahan F, Clark WM, Silver F, Rivera F for the PROACT Investigators. Intra-arterial prourokinase for acute ischemic stroke: the PROACT II Study: a randomized controlled trial. JAMA 1999; 282: 2003-11.
6. Marder VJ. Thrombolytic therapy: 2001. Blood Rev 2001; 15: 143-57.
7. Dotter CT, Rosch J, Seaman AJ. Selective clot lysis with low-dose streptokinase. Radiology 1974; 111: 31-7.
8. Heymans S, Vanderschueren S, Verhaeghe R, Stockx L, Lacroix H, Nevelsteen A, Larouche Y, Collen D. Outcome and one year follow-up of intra-arterial staphylokinase in 191 patients with peripheral arterial occlusions. Thromb Haemost 2000; 83: 666-71.
9. Marder VJ, Landskroner K, Novokhatny V, Zimmerman TP, Kong M, Kanouse JJ, Jesmok G. Plasmin induces local thrombolysis without causing hemorrhage: a comparison with tissue plasminogen activator in the rabbit. Thromb Haemost 2001; 86: 739-45.
10. Stewart D, Kong M, Novokhatny V, Jemok G, Marder VJ. Distinct dose-dependent effects of plasmin and TPA on coagulation and hemorrhage. Blood 2003; 101: 3002-7.
11. Jesmok G, Landskroner K, Taylor K, Novokhatny V, Zimmerman TP, Marder VJ. The effect of restricted blood flow on thrombolytic activity of locally delivered plasmin: comparison with TPA in rabbit models of venous and arterial thrombosis. In: Vossoughi J, Fareed J, Mousa SA, Karanian JW, eds. Thrombosis Research and Treatment: Bench to Bedside.
12. Fibrinolytic Therapy Trialists Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: colla-borative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 311.
13. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. Randomized risk of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994; 90: 1631-7.
14. O'Connor CM, Meese R, Carney R, Smith J, Conn E, Burks J, Hartman C, Roark S, Shadoff N, Heard M III, Mittler B, Collins G, Navetta F, Leimberger J, Lee K, Califf RM for the DUCCS Group. A randomized trial of intravenous heparin in conjunction with anistreplase (anisylated plasminogen streptokinase activator complex) in acute myocardial infarction: The Duke University Clinical Cardiology Study (DUCCS) I. J Am Coll Cardiol 1994; 23: 11-8.
15. Ouriel K, Veith FJ, Sasahara AA for the Thrombolysis or Peripheral Arterial Surgery (TOPAS) Investigators. A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. N Engl J Med 1998; 338: 1105-11.
16. Lebing W, Remington KM, Schreiner C, Paul HI. Properties of a new intravenous immunoglobulin (IGIV-C, 10%) produced by virus inacti-vation with caprylate and column chromatography. Vox Sang 2003; 84: 193-201.
17. Novokhatny V, Taylor K, Landskroner K, Jesmok G, Petteway S, Zimmerman T. Overview of plasmin as a local thrombolytic agent and in vitro studies. In: Vossoughi, J, Fareed, J, Mousa, SA, Karanian, JW, eds. Thrombosis Research and Treatment: Bench to Bedside.
18. Marder VJ, Shortell CK, Fitzpatrick PG, Kim C, Oxley D. An animal model of fibrinolytic bleeding based on the rebleed phenomenon: application to a study of vulnerability of hemostatic plugs of different age. Thromb Res 1992; 67: 31-40.
19. Montoney M, Gardell SJ, Marder VJ. Comparison of the bleeding potential of vampire bat salivary plasminogen activator (Bat-PA) versus tissue plasminogen activator (t-PA) in an experimental (rabbit) model. Circulation 1995; 91: 1540-4.
20. Ellis BC, Stransky A. A quick and accurate method for the determina-tion of fibrionogen in plasma. J Lab Clin Med 1961; 58: 477-88.
21. Proctor RR, Rapaport SI. The partial thromboplasmin time with kaolin: a simple screening test for first stage plasma clotting factor deficiencies. Am J Clin Pathol 1961; 36: 212-9.
22. Friberger P, Knos M, Gustavsson S, Aurell L, Claeson G. Methods for determination of plasmin, antiplasmin and plasminogen by means of substrate S-2251. Haemostasis 1978; 7: 138-45.
23. Bara L, Planes A, Samama MM. Occurrence of thrombosis and hae-morrhage, relationship with anti-Xa, anti-IIa activities, and D-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery. Br J Haematol 1999; 104: 230-40.
24. Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S. The weight-based dosing nomogram compared with a 'standard care' no-mogram: a randomized controlled trial. Ann Intern Med 1993; 119: 874-81.
25. Simoons ML, Maggioni AP, Knatterud G, Leimberger JD, de Jaeqere P, van Domburg R, Boersma E, Franzosi MG, Califf R, Schroder R, Braunweld E. Individual risk assessment for intracranial haemorrhage during thrombolytic therapy. Lancet 1993; 342: 1523-8.
26. Topol EJ. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 2001; 357: 1905-14.
27. Indications for fibrinolytic therapy in suspected acute myocardial in-farction. collaborative overview of early mortality and major morbidity results for all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Lancet 1994; 343: 311-22.